Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of Upadacitinib in Severe Alopecia Areata
2023-505061-82-01Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial in alopecia areata comparing Upadacitinib with Placebo (2 arms). Primary endpoint: Primary endpoint: SALT score ≤ 20 at Week 24. Planned start Mar 2024; status: authorised.
02
Drugs
upadacitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on 2023-505061-82-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505061-82-01.